Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line

Схожие документы

• Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations
  по: Arrieta, Oscar, et al.
  Опубликовано: (2020)
• Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors
  по: Westover, D, et al.
  Опубликовано: (2018)
• First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
  по: Nguyen, Kim-Son H, et al.
  Опубликовано: (2012)
• Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors()
  по: Nishino, Mizuki, et al.
  Опубликовано: (2012)
• Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance
  по: Jia, Peilin, et al.
  Опубликовано: (2013)